Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$3.3M
62 rounds on record
Latest round
$3.3M
Venture round · Jun 2024 · 2 yr ago
Team
58
US Form 5500 (plan participants) · Dec 2025 · -11% in a year
Grants
$78.5M
61 grants · CORDIS
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 3, 2025
Launched EpiCypher Launches Fiber-seq, a Breakthrough Multiomic Single-Molecule Genomics Assay · epicypher.com
Sep 3, 2025
Partnership PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow · Nasdaq
Jun 27, 2024
Raised a round Venture round $3.3M · SEC Form D
Jan 23, 2024
Partnership AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays · PRNewswire
2012
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $1.2M | — | CORDIS |
| Grant | Sep 2025 | $1.3M | — | CORDIS |
| Grant | Aug 2025 | $1M | — | CORDIS |
| Grant | Sep 2024 | $2.5M | — | CORDIS |
| Grant | Sep 2024 | $2M | — | CORDIS |
| Grant | Aug 2024 | $2.5M | — | CORDIS |
| Venture round | Jun 2024 | $3.3M | — | SEC Form D |
| Grant | Mar 2024 | $2.5M | — | CORDIS |
| Grant | Sep 2023 | $2.5M | — | CORDIS |
| Grant | Jul 2023 | $3M | — | CORDIS |
| Grant | Jul 2023 | $406k | — | CORDIS |
| Grant | Jun 2023 | $2.6M | — | CORDIS |
| Grant | May 2023 | $406k | — | CORDIS |
| Grant | Mar 2023 | $3M | — | CORDIS |
| Grant | Feb 2023 | $2.3M | — | CORDIS |
| Grant | Sep 2022 | $327k | — | CORDIS |
| Grant | Sep 2022 | $500k | — | CORDIS |
| Grant | Sep 2022 | $406k | — | CORDIS |
| Grant | Sep 2022 | $2M | — | CORDIS |
| Grant | Aug 2022 | $3M | — | CORDIS |
| Grant | Jun 2022 | $2M | — | CORDIS |
| Grant | May 2022 | $2.1M | — | CORDIS |
| Grant | Feb 2022 | $530k | — | CORDIS |
| Grant | Jan 2022 | $2M | — | CORDIS |
| Grant | Sep 2021 | $302k | — | CORDIS |
| Grant | Sep 2021 | $2M | — | CORDIS |
| Grant | Sep 2021 | $2M | — | CORDIS |
| Grant | Jul 2021 | $307k | — | CORDIS |
| Grant | May 2021 | $3M | — | CORDIS |
| Grant | Apr 2021 | $2M | — | CORDIS |
| Grant | Sep 2020 | $2M | — | CORDIS |
| Grant | Sep 2020 | $397k | — | CORDIS |
| Grant | Feb 2020 | $2.9M | — | CORDIS |
| Grant | Feb 2020 | $1.8M | — | CORDIS |
| Grant | Dec 2019 | $1.8M | — | CORDIS |
| Grant | Sep 2019 | $259k | — | CORDIS |
| Grant | Aug 2019 | $300k | — | CORDIS |
| Grant | Aug 2019 | $2M | — | CORDIS |
| Grant | Jun 2019 | $285k | — | CORDIS |
| Grant | Jun 2019 | $300k | — | CORDIS |
| Grant | Jan 2019 | $300k | — | CORDIS |
| Grant | Sep 2018 | $2M | — | CORDIS |
| Grant | Sep 2018 | $300k | — | CORDIS |
| Grant | Sep 2018 | $285k | — | CORDIS |
| Grant | Aug 2018 | $300k | — | CORDIS |
| Grant | Jun 2018 | $300k | — | CORDIS |
| Grant | Jun 2018 | $1.7M | — | CORDIS |
| Grant | Mar 2018 | $2.1M | — | CORDIS |
| Grant | Mar 2018 | $300k | — | CORDIS |
| Grant | Feb 2018 | $300k | — | CORDIS |
| Grant | Feb 2018 | $1.7M | — | CORDIS |
| Grant | Sep 2017 | $1.6M | — | CORDIS |
| Grant | Aug 2017 | $1.5M | — | CORDIS |
| Grant | Aug 2017 | $225k | — | CORDIS |
| Grant | Jun 2017 | $225k | — | CORDIS |
| Grant | Mar 2017 | $225k | — | CORDIS |
| Grant | Sep 2016 | $225k | — | CORDIS |
| Grant | Sep 2016 | $224k | — | CORDIS |
| Grant | Sep 2016 | $224k | — | CORDIS |
| Grant | Jul 2016 | $224k | — | CORDIS |
| Grant | Mar 2016 | $225k | — | CORDIS |
| Grant | Dec 2015 | $1.6M | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | EPICYPHER, INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
James BoneExecutive Officer, DirectorSEC Form D
News
CUT&RUN Decodes Drug Resistance Mechanisms
Beyond RNA-seq: Applying CUT&RUN to Decode Drug Resistance and Inform Rational Combination Therapies Key Takeaways:RNA-seq and ATAC-seq reveal transcriptional rewiring associated with cancer drug resistance; however, they only indirectly implicate the res
Read more
Report
EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research
/PRNewswire/ -- EpiCypher and New England Biolabs (NEB) today announced an expanded strategic partnership to co-develop next-generation tools for...
Read more
Report
Fiber-seq Applied to Brain Cells Enhances Neuro Research
Fiber-seq Provides a More Complete View of the Human Brain Epigenome Fiber-seq: A Solution to Uncover Unmapped Epigenomic RegionsChromatin profiling assays employed to detect accessible chromatin regions represent a widely used means of generating genome-
Read more
Report
Tracing the H3K36me2 Signal: CUT&RUN Enabled Insights into NSD2 Inhibitor Response
Interrupting the epigenetic programs that drive tumor growth is a promising avenue for cancer therapy, and NSD2 is emerging as a compelling target. However, robust technologies are needed to define the mechanism of action of NSD2-targeted therapeutics, pa
Read more
Report
Placing CUT&RUN Data Analysis Back in the Hands of Biologists
CUT&RUN and CUT&Tag have become gold-standard methods for profiling protein-DNA interactions, offering high resolution, low background, and efficient sequencing. While these assays dramatically simplified experimental workflows, data analysis has remained
Read more
Report
Redefining High-Resolution DNA Methylation Mapping
Durham, NC - Oct. 16, 2025 (The Scientist) - Winning a spot in the 2025 Top Innovations contest's Lab Research Tools category, the CUTANA meCUT&RUN kit harnesses engineered proteins to capture DNA methylation sites at scale.DNA methylation is an epigeneti
Read more
Report
Headed to SfN? 4 Ways CUT&RUN and CUT&Tag Are Advancing Neuroscience
Epigenetic mechanisms shape nearly every aspect of neurobiology-from guiding early neural development to regulating plasticity, cognition, and responses to injury or disease. Interest in chromatin profiling in neuroscience continues to grow, as researcher
Read more
Report
Major Updates to CUTANA CUT&Tag Kits: Improved Performance at Lower Costs
Funding challenges are a reality for many researchers, and we want to make sure innovation doesn't slow down because of it. That's why our team has introduced major updates to CUTANA CUT&Tag assays - making them more streamlined, affordable, and accessibl
Read more
Report
Fiber-seq 101: A Multiomic Assay That Goes Beyond ATAC-seq
How do cells control when and where genes are expressed? The answer lies in a complex interplay of regulatory proteins that govern chromatin accessibility and architecture. These processes establish cell identity and maintain genome stability, and when di
Read more
Report
Multivalent binding of the tardigrade Dsup protein to chromatin promotes yeast survival and longevity upon exposure to oxidative damage
Tardigrades are remarkable in their ability to survive extreme environments. The damage suppressor (Dsup) protein is thought to contribute to their extreme resistance to reactive oxygen species (ROS) generated by irradiation. Here we show that expression
Read more
Report
Show more news
People

James Bone
Executive Officer, Director

Mark Bedford
Director

Or Gozani
Director

Michael-Christopher Keogh
Director

Andrew Barry
Director

Joe McMahon
Director

Brian Strahl
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Durham
United States
HQ
Cambridge
United States
Regional office
United Kingdom - Cambridge Bioscience
Financials
Total raised
$81.8M
Latest round
Grant
Funding rounds
62
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2025 | $1.2M | Details |
| Grant | 2025 | $1.3M | Details |
| Grant | 2025 | $1M | Details |
| Grant | 2024 | $2.5M | Details |
| Grant | 2024 | $2M | Details |
| Grant | 2024 | $2.5M | Details |
| Venture - Series Unknown | 2024 | $3.3M | Details |
| Grant | 2024 | $2.5M | Details |
| Grant | 2023 | $2.5M | Details |
| Grant | 2023 | $3M | Details |
| Grant | 2023 | $406k | Details |
| Grant | 2023 | $2.6M | Details |
| Grant | 2023 | $406k | Details |
| Grant | 2023 | $3M | Details |
| Grant | 2023 | $2.3M | Details |
| Grant | 2022 | $327k | Details |
| Grant | 2022 | $500k | Details |
| Grant | 2022 | $406k | Details |
| Grant | 2022 | $2M | Details |
| Grant | 2022 | $3M | Details |
| Grant | 2022 | $2M | Details |
| Grant | 2022 | $2.1M | Details |
| Grant | 2022 | $530k | Details |
| Grant | 2022 | $2M | Details |
| Grant | 2021 | $302k | Details |
| Grant | 2021 | $2M | Details |
| Grant | 2021 | $2M | Details |
| Grant | 2021 | $307k | Details |
| Grant | 2021 | $3M | Details |
| Grant | 2021 | $2M | Details |
| Grant | 2020 | $2M | Details |
| Grant | 2020 | $397k | Details |
| Grant | 2020 | $2.9M | Details |
| Grant | 2020 | $1.8M | Details |
| Grant | 2019 | $1.8M | Details |
| Grant | 2019 | $259k | Details |
| Grant | 2019 | $300k | Details |
| Grant | 2019 | $2M | Details |
| Grant | 2019 | $285k | Details |
| Grant | 2019 | $300k | Details |
| Grant | 2019 | $300k | Details |
| Grant | 2018 | $2M | Details |
| Grant | 2018 | $300k | Details |
| Grant | 2018 | $285k | Details |
| Grant | 2018 | $300k | Details |
| Grant | 2018 | $300k | Details |
| Grant | 2018 | $1.7M | Details |
| Grant | 2018 | $2.1M | Details |
| Grant | 2018 | $300k | Details |
| Grant | 2018 | $300k | Details |
| Grant | 2018 | $1.7M | Details |
| Grant | 2017 | $1.6M | Details |
| Grant | 2017 | $1.5M | Details |
| Grant | 2017 | $225k | Details |
| Grant | 2017 | $225k | Details |
| Grant | 2017 | $225k | Details |
| Grant | 2016 | $225k | Details |
| Grant | 2016 | $224k | Details |
| Grant | 2016 | $224k | Details |
| Grant | 2016 | $224k | Details |
| Grant | 2016 | $225k | Details |
| Grant | 2015 | $1.6M | Details |
